Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) will be releasing its earnings data before the market opens on Wednesday, February 8th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.64 per share for the quarter. Teva Pharmaceutical Industries has set its FY22 guidance at $2.40-$2.60 EPS.Investors that wish to listen to the company's conference call can do so using this link.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The firm had revenue of $3.60 billion during the quarter, compared to analysts' expectations of $3.86 billion. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Get
Teva Pharmaceutical Industries alerts:
Teva Pharmaceutical Industries Stock Up 2.7 %
Shares of NYSE TEVA opened at $10.54 on Wednesday. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.44. The company has a market cap of $11.71 billion, a P/E ratio of -9.09 and a beta of 1.19. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. The stock has a fifty day moving average price of $9.57 and a 200 day moving average price of $9.16.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut shares of Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and reduced their price target for the stock from $11.00 to $10.00 in a research report on Monday, November 14th. BMO Capital Markets lowered their price objective on shares of Teva Pharmaceutical Industries from $11.00 to $10.00 and set a "market perform" rating on the stock in a research note on Monday, November 7th. Piper Sandler decreased their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, November 23rd. Jefferies Financial Group cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating and lifted their price objective for the stock from $10.00 to $12.00 in a research report on Thursday, January 19th. Finally, StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They set a "buy" rating for the company. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.67.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Ensign Peak Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 14.9% in the 3rd quarter. Ensign Peak Advisors Inc now owns 54,450 shares of the company's stock worth $439,000 after acquiring an additional 7,050 shares in the last quarter. Weiss Multi Strategy Advisers LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter worth approximately $393,000. United Services Automobile Association bought a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $371,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in Teva Pharmaceutical Industries by 16.3% during the first quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 39,322 shares of the company's stock valued at $369,000 after acquiring an additional 5,500 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $285,000. 50.39% of the stock is owned by institutional investors.
Teva Pharmaceutical Industries Company Profile
(Get Rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Featured Stories
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
